[1]宋泽娟,徐静,李婵.羟苯磺酸钙联合康柏西普治疗糖尿病性黄斑水肿的疗效和安全性[J].眼科新进展,2021,41(1):075-78.[doi:10.13389/j.cnki.rao.2021.0016]
　SONG Zejuan,XU Jing,LI Chan.Clinical efficacy and safety of calcium dobesilate combined with conbercept in the treatment of diabetic macular edema[J].Recent Advances in Ophthalmology,2021,41(1):075-78.[doi:10.13389/j.cnki.rao.2021.0016]
点击复制

羟苯磺酸钙联合康柏西普治疗糖尿病性黄斑水肿的疗效和安全性/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
41卷
期数:
2021年1期
页码:
075-78
栏目:
应用研究
出版日期:
2021-01-05

文章信息/Info

Title:
Clinical efficacy and safety of calcium dobesilate combined with conbercept in the treatment of diabetic macular edema
作者:
宋泽娟; 徐静; 李婵
710002　陕西省西安市，西安市第一医院眼科
Author(s):
SONG Zejuan; XU Jing; LI Chan
Department of Ophthalmology,Xi’an First Hospital,Xi’an 710002,Shaanxi Province,China
关键词:
羟苯磺酸钙; 康柏西普; 糖尿病性黄斑水肿; 血管内皮生长因子; 基质细胞衍生因子1
Keywords:
calcium dobesilate;  conbercept;  diabetic macular edema;  vascular endothelial growth factor;  stromal cell derived factor-1
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2021.0016
文献标志码:
A
摘要:
目的　探讨羟苯磺酸钙联合康柏西普治疗糖尿病性黄斑水肿（diabetic macular edema，DME）的临床疗效和安全性。方法　选取DME患者86例104眼，随机分为康柏西普眼用注射液(conbercept ophthalmic injection，COI)组（43例50眼）和联合组（43例54眼）。COI组给予患者玻璃体内注射COI治疗，联合组在COI组基础上给予患者羟苯磺酸钙胶囊治疗。治疗3个月后，比较两组患者房水血管内皮生长因子（VEGF）、基质细胞衍生因子1（stromal cell derived factor-1，SDF-1）含量以及黄斑中央视网膜厚度（CMT）、最佳矫正视力（BCVA）、并发症发生情况。结果　治疗3个月后，联合组和COI组患者房水VEGF、SDF-1含量均明显低于治疗前，联合组均低于COI组，差异均有统计学意义（均为P<0.05）。治疗1个月、3个月后，联合组和COI组CMT均低于治疗前，且联合组CMT均低于COI组，差异均有统计学意义（均为P<0.05）。治疗1个月、3个月后，联合组和COI组BCVA均明显高于治疗前，联合组BCVA均高于COI组，差异均有统计学意义（均为P<0.05）。治疗中和治疗后，COI组和联合组分别出现眼压升高3眼和2眼，结膜充血各2眼，玻璃体积血各1眼；两组并发症发生率比较，差异无统计学意义（P>0.05）。结论　羟苯磺酸钙联合康柏西普可有效降低DME患者房水VEGF、SDF-1水平，降低CMT，提高BCVA，且安全性好。
Abstract:
Objective　To explore the clinical efficacy and safety of calcium dobesilate combined with conbercept in the treatment of diabetic macular edema (DME).Methods　The 104 eyes of 86 patients with DME were randomly divided into the conbercept ophthalmic injection (COI) group (50 eyes of 43 patients) and combined group (54 eyes of 43 patients).The COI group was treated with intravitreal COI injection, and the combined group was treated with calcium dobesilate capsules on the basis of the COI group. The levels of vascular endothelial growth factor (VEGF), stromal cell-derived factor-1 (SDF-1), central macular retinal thickness (CMT), best corrected visual acuity (BCVA), and complications 3 months after treatment were detected and compared between the two groups. Results　After 3 months of treatment, the levels of VEGF and SDF-1 in aqueous humor of the combined group and COI group were significantly lower than those before the treatment, and the combined group was lower than that of the COI group, and the differences were statistically significant (all P<0.05). After 1 month and 3 months of treatment, the CMT of the combined group and the COI group were lower than those of the before treatment, and the CMT of the combined group was lower than that of the COI group, and the differences were statistically significant (all P<0.05). After 1 month and 3 months of treatment, the BCVA of the combined group and the COI group were significantly higher than those of the before treatment, and the BCVA of the combined group was higher than that of the COI group, and the differences were statistically significant (all P<0.05). During and after treatment, there were 3 eyes and 2 eyes with intraocular pressure increased,2 eyes and 2 eyes with high conjunc-tival congestion, 1 eye and 1 eye with vitreous hemorrhage in the COI group and the combined group, respectively, but there were no significant differences in the incidence of complications between the two groups (all P>0.05). Conclusion　For the DME patients, calcium dobesilate combined with conbercept can effectively reduce the levels of VEGF and SDF-1 in the aqueous humor, reduce CMT, increase BCVA, and has good safety.

参考文献/References:

［1］　LIU S,WANG D,CHEN F,ZHANG X.Hyper reflective foci in OCT image as a biomarker of poor prognosis in diabetic macular edema patients treating with conbercept in China［J］.BMC Ophthalmol,2019,19(1):157.
［2］　李磊,王刚,马远程.眼底激光联合羟苯磺酸钙治疗糖尿病视网膜病变60例疗效分析［J］.安徽医药,2019,23(7):1452-1455.
LI L,WANG G,MA Y C.Clinical analysis of fundus laser treatment combined with oralcalcium dobesilate capsules for diabetic retinopathy［J］.Anhui Med Pharm J,2019,23(7):1452-1455.
［3］　万晶,孙会,清苏艺.雷珠单抗联合玻璃体切割术对PDR患者视网膜新血管形成的影响［J］.检验医学与临床,2017,14(10):1453-1455.
WANG J,SUN H,QING S Y.Effect of combined vitrectomy with monoclonal antibody and monoclonal antibody on retinal neovascularization in patients with PDR［J］.Lab Med Clin,2017,14(10):1453-1455.
［4］　中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）［J］.中华糖尿病杂志,2018,10(1):4-67.
Chinese Diabetes Society.Chinese guidelines for the prevention and treatment of type 2 diabetes mellitus (2017 Edition)［J］.Chin J Diabetes Mellitus,2018,10(1):4-67.
［5］　李凤鸣.中华眼科学［M］.第2版.北京:人民卫生出版社,2005:2165-2171.
LI F M.Chinese ophthalmology ［M］.2nd Edition.Beijing:People’s Health Publishing House,2005:2165-2171.
［6］　LIU W S,LI Y J.Comparison of Conbercept and ranibizumab for the treatment efficacy of diabetic macular edema:a Meta-analysis and systematic review［J］.Int J Ophthalmol,2019,12(9):1479-1486.
［7］　LIU Z Y,MA X J,LIAO D Y,LIU X D,BAI L,YAO J,et al.Association of urinary albumin excretion with central foveal thickness and intravitreal conbercept treatment frequency in patients with diabetic macular edema［J］.Int J Ophthalmol,2019,12(10):1598-1604.
［8］　牛红霞,吉昂.玻璃体腔注射康柏西普联合视网膜光凝治疗糖尿病性黄斑水肿的疗效观察［J］.解放军医学杂志,2018,43(3):268-270.
NIU H X,JI A.Effect of intravitreal injection of conbercept combined with retinal photocoagulation in the treatment of diabetic macular edema［J］.Med J Chin PLA,2018,43(3):268-270.
［9］　XU Y,RONG A,XU W,NIU Y,WANG Z.Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema:a real-life clinical practice study［J］.BMC Ophthalmol,2017,17(1):158.
［10］　胡军华,刘春兰,夏侯梨,廖莹琳,胡明生,毛蕾,等.眼底激光联合羟苯磺酸钙治疗糖尿病视网膜病变的效果观察［J］.中国当代医药,2017,24(29):88-90.
HU J H,LIU C L,XIA H L,LIAO Y L,HU M S,MAO L,et al.Observation of curative effect of fundus laser combined with Calcium Dobesilate in the treatment of diabetic retinopathy［J］.Chin Mod Med,2017,24(29):88-90.
［11］　MOON S W,SHIN Y U,CHO H,BAE S H,KIM H K.Effect of grape seed proanthocyanidin extract on hard exudates in patients with non-proliferative diabetic retinopathy［J］.Medicine (Baltimore),2019,98(21):e15515.
［12］　张军辉,王媛媛.康柏西普联合玻璃体切除术对糖尿病性视网膜病变患者房水两种生长因子的影响［J］.中华眼外伤职业眼病杂志,2019,41(6):436-441.
ZHANG J H,WANG Y Y.Effect of conbercept combined with vitrectomy on two growth factors of aqueous humor in patients with diabetic retinopathy［J］.Chin J Ocul Traum Occupat Eye Dis,2019,41(6):436-441.
［13］　DENG L,JIA J,YAO J,XU Z.Stromal cell-derived factor 1 (SDF-1) and its receptor CXCR4 improves diabetic retinopathy［J］.Biosci Biotechnol Biochem,2019,83(6):1072-1076.
［11］　吕学伟.羟苯磺酸钙对糖尿病视网膜病变的控制效果及相关活性因子的影响［J］.中国卫生工程学,2019,18(4):614-616.
LYU X W.Effect of calcium dobesilate on diabetic retinopathy and related active factors［J］.Chin J Public Health Eng,2019,18(4):614-616.
［15］　ZHOU Y,QI C,LI S,SHAO X,MOU S,NI Z.Diabetic nephropathy can be treated with calcium dobesilate by alleviating the chronic inflammatory state and improving endothelial cell function［J］.Cell Physiol Biochem,2018,51(3):1119-1133.

相似文献/References:

[1]楚静 陈忠平.普拉洛芬及羟苯磺酸钙在糖尿病患者白内障手术中的应用[J].眼科新进展,2013,33(8):000.
[2]张娣,张玲,杨静,等.玻璃体内注射康柏西普联合手术及全视网膜光凝治疗新生血管性青光眼[J].眼科新进展,2015,35(12):1170.[doi:10.13389/j.cnki.rao.2015.0320]
　ZHANG Di,ZHANG Ling,YANG Jing,et al.Intravitreal injection of conbercept combined with operation and panretinal photocoagulation for neovascular glaucoma[J].Recent Advances in Ophthalmology,2015,35(1):1170.[doi:10.13389/j.cnki.rao.2015.0320]
[3]李娜,张杰,高荣玉,等.单次注射康柏西普治疗渗出型AMD患者RPE隆起面积与容积变化[J].眼科新进展,2016,36(2):172.[doi:10.13389/j.cnki.rao.2016.0047]
　LI Na,ZHANG Jie,GAO Rong-Yu,et al.Changes of retinal pigment epithelium uplift area and volume in exudative age-related macular degeneration after once injection of conbercept[J].Recent Advances in Ophthalmology,2016,36(1):172.[doi:10.13389/j.cnki.rao.2016.0047]
[4]王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性[J].眼科新进展,2016,36(5):471.[doi:10.13389/j.cnki.rao.2016.0126]
　WANG Chen,LI Dong-Hao,WEN Yi-Yi.Intravitreal injection of conbercept combined with selective peripheral retinal photocoagulation for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(1):471.[doi:10.13389/j.cnki.rao.2016.0126]
[5]王玮,徐玲娟,蔡苏博,等.角膜基质及结膜下单次注射康柏西普治疗角膜新生血管的疗效及安全性[J].眼科新进展,2016,36(8):725.[doi:10.13389/j.cnki.rao.2016.0192]
　WANG Wei,XU Lin-Juan,CAI Su-Bo,et al.Efficacy and safety of one dose intrastromal and subconjunctival conbercept injection for corneal neovascularization[J].Recent Advances in Ophthalmology,2016,36(1):725.[doi:10.13389/j.cnki.rao.2016.0192]
[6]史志洁,张金嵩,吕晓贝.玻璃体内注射康柏西普联合手术治疗伴玻璃体积血的新生血管性青光眼[J].眼科新进展,2016,36(8):751.[doi:10.13389/j.cnki.rao.2016.0200]
　SHI Zhi-Jie,ZHANG Jin-Song,LV Xiao-Bei.Intravitreal injection of conbercept and surgical treatment for neovascular glaucoma combined with vitreous hemorrhage[J].Recent Advances in Ophthalmology,2016,36(1):751.[doi:10.13389/j.cnki.rao.2016.0200]
[7]罗顺利,许泽广,梁春正.复合式小梁切除术联合康柏西普治疗新生血管性青光眼[J].眼科新进展,2016,36(11):1076.[doi:10.13389/j.cnki.rao.2016.0287]
　LUO Shun-Li,XU Ze-Guang,LIANG Chun-Zheng.Compound trabeculectomy with conbercept for neovascular glaucoma[J].Recent Advances in Ophthalmology,2016,36(1):1076.[doi:10.13389/j.cnki.rao.2016.0287]
[8]吴若欣,徐洁慧,温积全,等.玻璃体内注射康柏西普对渗出性老年性黄斑变性患者脉络膜厚度的影响[J].眼科新进展,2016,36(12):1172.[doi:10.13389/j.cnki.rao.2016.0312]
　WU Ruo-Xin,XU Jie-Hui,WEN Ji-Quan,et al.Effects of intravitreal conbercept injections on choroidal thickness in exudative age-related macular degeneration[J].Recent Advances in Ophthalmology,2016,36(1):1172.[doi:10.13389/j.cnki.rao.2016.0312]
[9]薛鹏程,游志鹏,付书华,等.23G玻璃体切割术前、术中辅助玻璃体内注射康柏西普治疗增生型糖尿病视网膜病变（PDR）的疗效分析[J].眼科新进展,2017,37(5):458.[doi:10.13389/j.cnki.rao.2017.0116]
　XUE Peng-Cheng,YOU Zhi-Peng,FU Shu-Hua,et al.Preoperative and intraoperative adjunctive intravitreal conbercept in 23G vitrectomy for proliferative diabetic retinopathy[J].Recent Advances in Ophthalmology,2017,37(1):458.[doi:10.13389/j.cnki.rao.2017.0116]
[10]朱磊,田晓燕,刘涛.玻璃体内注射康柏西普治疗湿性年龄相关性黄斑变性的临床观察[J].眼科新进展,2017,37(5):473.[doi:10.13389/j.cnki.rao.2017.0120]
　ZHU Lei,TIAN Xiao-Yan,LIU Tao.Intravitreal injection of conbercept for wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2017,37(1):473.[doi:10.13389/j.cnki.rao.2017.0120]

备注/Memo

备注/Memo:
N/A
更新日期/Last Update: 2021-01-05